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Abstract
Background: Despite guidelines for cervical cancer prevention in low-resource countries, a very small proportion of
women in these settings undergo screening, and even fewer women are successfully treated. Using pilot data from
western Kenya and World Health Organization recommendations, we developed a protocol to implement
evidence-based cervical cancer screening and linkage to treatment strategies to the rural communities. We describe
the protocol for a cluster-randomized trial to compare two implementation strategies for human-papillomavirus
(HPV)-based cervical cancer screening program using metrics described in the RE-AIM (reach, efficacy, adaption,
implementation and maintenance) framework.
Methods: The study is a three-year, two-phase cluster-randomized trial in 18 communities in western Kenya. During
Phase 1, six control communities were offered screening in health facilities; and six intervention communities were
offered screening in community health campaigns. Screening was done with human-papillomavirus testing
through self-collected specimens. Phase 1 ended and we are working in partnership with communities to further
contextualize the implementation strategy for screening, and develop an enhanced linkage to treatment plan. This
plan will be tested in an additional six communities in Phase 2 (enhanced intervention). We will compare the reach,
efficacy, cost-effectiveness and adaptability of the implementation strategies.
Discussion: Effective low-cost cervical cancer prevention technologies are becoming more widely available in low- and
middle-income countries. Despite increasing government support for cervical cancer prevention, there remains a sizeable
gap in service availability. We will use implementation science to identify the most effective strategies to fill this gap
through development of context-specific evidence-based solutions. This protocol design and results can help guide
implementation of cervical cancer screening in similar settings, where women are most underserved and at highest risk
for disease.
Trial registration: This trial is registered at ClinicalTrials.gov, NCT02124252.
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Background
Despite the fact that cervical cancer is highly preventable
through vaccination and organized screening programs,
over 500,000 women worldwide are diagnosed with the
disease every year [1]. About 9 out of 10 cervical cancer
deaths occur in low-resource countries, with a particularly
high burden in sub-Saharan Africa, where the mortality
rate is 85% [2, 3]. The inequality between high and low-
resource countries is mainly due to lack of screening in
low-resource countries, which lack the health care infra-
structure required for the cytology-based screening pro-
grams that have dramatically reduced the disease burden
in wealthier countries. The World Health Organization
(WHO) recommends alternative cervical cancer preven-
tion techniques and protocols for low-resource countries
that employ low-cost or simple-to-use screening technolo-
gies [4]. One such strategy – high-risk human papilloma-
virus (HPV) testing– has been shown to reduce the
incidence and mortality from cervical cancer when
coupled with outpatient treatment for women with HPV-
positive results [5].
In addition to effective screening tools, the impact of
cervical cancer prevention programs depends on two
main context-specific factors: (1) women’s access to
screening and (2) successful acquisition of treatment for
women who screen positive. Access to both screening
and treatment is most challenging in poor rural areas,
due to geographic and infrastructure constraints [6, 7].
Most health care in rural areas takes place in small
health facilities with limited space, staffing, and equip-
ment, making it challenging to implement same-day
“screen & treat” strategies that have been proposed to
overcome barriers to treatment access [8]. So, despite
the development of guidelines for cervical cancer screen-
ing that employed evidence-based technologies and
lower resource protocols, the lack of rigorously tested,
context-specific implementation strategies has left a gap
between policy and practice.
In order to develop a context-specific, sustainable im-
plementation strategy, we undertook formative work to
identify local barriers and facilitators for cervical cancer
screening in government-supported health facilities in
rural western Kenya, an area of East Africa with a high
cervical cancer burden and screening rates as low as 3%
[9, 10]. We found that access to screening was limited
by lapses in service availability and lack of clinic attend-
ance for preventive care [11]. When services were avail-
able, both providers and patients found the need for a
pelvic exam limited the acceptability of cervical cancer
screening. Based on the facility-based barriers, we devel-
oped and piloted a highly successful community health
campaign model for screening, consisting of outreach
followed by a brief campaign held in a central site in the
community, offering on-site screening and referrals for
treatment [12]. An advantage of community-based
screening is that only screen-positive women need to
visit health facilities for follow-up care, reducing the visit
burden for both woman and facilities, and allowing
resources to be directed toward strategies to increase
treatment uptake, such as intensified follow-up, trans-
portation assistance or mobile units that bring treatment
to remote villages. Thus, as has been seen in other
health services [13–15], by combining community-
screening with enhanced linkage strategies, our approach
could maximize the health impact by increasing the
number of women screening and the proportion
successfully accessing treatment.
To address the reluctance around pelvic exams, we
chose to offer screening with self-collected specimens
for HPV testing, an evidence-based strategy that would
eliminate pelvic exams for initial screening, further
increasing screening acceptance and efficiency. We
developed a study protocol that will allow us to compare
two context-specific implementation strategies for an
HPV-based cervical cancer prevention program through
a cluster-randomized trial of HPV-based cervical cancer
screening in community-health campaigns versus health
facilities using the RE-AIM framework [16, 17]. This
paper describes the study protocol (V 3.0, 20 July 2017)
and the plan to evaluate the adaptability, comparative ef-
fectiveness and cost-effectiveness of these two strategies.
Methods
Study design and setting
The study is a two-phase cluster randomized trial in
western Kenya to evaluate reach, effectiveness, cost-
effectiveness and maintenance of two implementation
strategies for a cervical cancer prevention protocol that
consists of four critical, evidence-based components:
(1).HPV and cervical cancer outreach and
education. In western Kenya, we found that women’s
baseline knowledge and perception of cervical cancer
risk is low; a brief educational intervention provided
by community health workers in primary care clinics
improved these baseline factors and increased
women’s intention to screen [18].
(2).HPV-testing using self-collected specimens with
referral for treatment based on a single positive
result. An HPV-based screening strategy is effective at
reducing incidence of cervical pre-cancer and invasive
cancer when women with screen-positive results
undergo cryotherapy [5, 19, 20]. Self-collected
specimens are highly accurate, with comparable results
to provider-collection for the detection of high-grade
cervical precancer [21–23] Women have consistently
found self-sampling acceptable and preferable to
provider-testing [24–26]; this finding has been
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supported in studies from sub-Saharan Africa [27, 28].
Studies in various countries have shown that a self-
collection strategy increases screening uptake by
women not attending clinics [29–34].
(3).Notification of screening results using text
messaging. Based on our prior experience with
mobile health interventions [35, 36] and the high
rates of cell phone use in western Kenya [37], HPV
test results were sent to all women via text message
with instructions about appropriate follow-up as
recommended by the Kenya Ministry of Health
guidelines.
(4).Treatment with cryotherapy unless
contraindicated by cervical exam. Cryotherapy is a
low-cost, effective treatment method that can be safely
carried out by mid-level providers in low-resource
settings [38, 39]. Women who are not candidates for
cryotherapy (i.e. lesions too large or abnormal cervical
anatomy) were offered Loop Electrosurgical Excision
Procedure carried out in the County Hospital.
Together, HPV testing followed by cryotherapy for
women who test positive reflect the current WHO
recommendations [40].
In Phase 1 of this study, we compared two implemen-
tation strategies that incorporated these four evidence-
based elements of screening. Based on our preliminary
data, we found that reaching and attending a health
facility for preventive care was a significant barrier to
screening for many women. Therefore, the main object-
ive was to compare a model offering screening in brief,
high throughput community health campaigns to that of
a standard of care in which screening was offered in
local health facilities using the metrics defined in the
modified RE-AIM framework.
In Fig. 1, we present an overall schema of the cluster-
randomized trial. In Phase 1, six communities were ran-
domized to the intervention: HPV screening carried out
in community health campaigns. The remaining six
were comparison communities: HPV testing offered in
government health facilities. HPV-test positive women
in all communities were referred to the County hospital
for immediate treatment, which is considered standard
linkage to treatment.
Development of an enhanced strategy for linkage to
treatment: After Phase 1, we have an “inter-phase inter-
vention development” period in which we are evaluating
the results from the trial. The outcomes from the quali-
tative and quantitative measures will be used to refine
the screening intervention using context-specific details
and develop an enhanced strategy for linkage to treat-
ment. Although we have identified factors that enable
and inhibit women’s access to treatment, we chose to
wait until after Phase 1 for the development of the
enhanced strategy for linkage to treatment in order to
truly work in partnership with the community. The de-
layed development of the linkage to treatment strategy
has allowed us obtain a baseline measure of the efficacy
of standard referrals and identify factors that would in-
fluence women’s access to care in this setting.
After developing the strategy for enhanced linkage, we
will pilot and then test the linkage to treatment strategy
as part of an “enhanced intervention” in the six commu-
nities that served as controls in Phase 1. Using these
communities for the enhanced intervention increases
the efficiency of the study in two ways: i. we will have
done community enumeration and engagement, and ii.
we will compare linkage to treatment outcomes from
these “enhanced intervention” communities to the inter-
vention communities from Phase 1.
Study activities
Study preparation
 Community enumeration and randomization:
Prior to the initiation of the cluster randomized
trial, we characterized the study communities using
a combination of census data, health facility
Fig. 1 Two-phase cluster-randomized trial design
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information, mapping and prospective demographic
data. We identified communities of approximately
7500 people in three sub-counties of Migori County
in western Kenya (population: 350,000, 65 govern-
ment health facilities). Population estimates were
calculated using the 2009 Kenyan census data with
population growth estimates for 2015 and 2014, a
method that was validated through door-to-door
enumeration for a recent large-scale community
randomized trial in rural western Kenya [41].
Eligible communities had at least one government
health facility with capacity to provide HPV testing,
support from community leaders for the community
outreach and/or health campaigns, accessibility to
health centers via a maintained transportation route
and sufficient distance from other potential study
sites to limit contamination between arms (buffer
zones). As our target group is women in rural
communities, we excluded urban settings or
communities in which the nearest health center is
Migori County Hospital and those that were taking
part in a cluster-randomized trial of large-scale
community-health campaigns for HIV-testing [41].
We conducted unmatched randomization using a
random number generator on Stata 10. The
unmatched design will allow us to consider the
relationship between community-level factors and
our outcomes of interest. After communities were
chosen, population estimates were refined through
household enumeration done by community health
workers assigned to villages and sub-locations within
the communities.
 Provider and key stakeholder focus groups:
Clinicians and community health workers
(“providers”) within the community health
campaigns and health facilities participated in focus
group discussions to provide baseline data about
perceived barriers and strategies to facilitate HPV
screening uptake during the planning and
implementation adaptation period of the study.
Although we sought key stakeholder input
throughout the development of the implementation
strategies, we held three focus group discussions
with key stakeholders in the intervention and
control communities for Phase 1 (community chiefs,
leaders of women’s groups, reproductive health
coordinator, medical superintendent and Charge
Nurse of Migori District Hospital). The goals of
these focus groups were to obtain a group
perspective on the intervention as planned for their
communities, any anticipated challenges and
strategies to optimize the screening strategy in both
arms. Focus group discussions were analyzed using
the theoretical domains framework, which mapped
behaviors to intervention strategies, using evidence-
based principles of behavior change [42].
 Training and finalization of the screening
protocol.We used educational modules piloted in
western Kenya to provide standardized training in
cervical cancer counseling and HPV-self testing to
community health workers and clinicians [43]. The
community health workers received training in
community outreach messaging, delivery of the
educational module in the community health
campaign setting, and teaching women how to
perform self-collection of HPV specimens. In
addition to the general training, clinicians had
undergone Ministry of Health-supported training to
learn the cervical cancer screening protocol,
including follow-up and pre-treatment exams. Two
nurses who had undergone cryotherapy training
were identified and supervised for ten cryotherapies
at the County Hospital prior to study initiation.
Cluster randomized trial: Phase 1
After community enumeration, training and protocol
finalization, we launched the cluster-randomized trial in
the six control and six intervention communities in
Migori County. (Figure 2) Phase 1 of the trial, consisting
of the activities listed below, took place over the course
of 1 year.
 Outreach and education: In all communities,
information about cervical cancer screening and the
opportunity to learn more about HPV-based testing
were provided through community outreach,
including fliers, posters and brief informational
sessions in markets, churches and women’s group
meetings. Women and community leaders were
provided with information on how to access cervical
cancer screening in their community, e.g. location of
clinic or timing and location of community health
campaign. In all communities, women were invited
to participate in a brief, standardized cervical cancer
education module, either at the health campaign or
in the health facility. The module is approximately
15 min and covers topics ranging from simple
anatomy, definition of cervical cancer and HPV, how
screening works, what treatment is available for
precancerous lesions, and how to perform HPV
self-testing.
 Community-based testing (intervention group):
In six communities randomized to community-based
HPV testing, community outreach teams carried out
two-week community health campaigns in which
HPV-testing was offered through self-collection. In
order to reach the entire community, the campaign
moved to multiple sites over the two-week period,
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with approximately one to 2 days at each site. The
campaigns consisted of health education and informed
consent, after which a health worker provided
additional instructions about self-collection and
recorded a mobile phone number before dispensing
the HPV testing kit. The woman then would go to a
private area in the campaign tent to self-collect the
specimen and returned the completed collection kit to
the health worker prior to leaving.
 Clinic-based testing (comparison group): In the
six communities randomized to the control arm
(clinic-based testing), women were directed through
community outreach to go to their local health facility
during regular clinic hours to carry out screening. At
the clinic, a health worker offered the educational
module, obtained informed consent and provided
additional information about self-collection, and
recorded a mobile phone number before dispensing
the HPV testing kit and instructions.
 HPV testing: While HPV test results are not the
primary outcome for this study, the accuracy and
reproducibility of measurements are essential for
outcomes in both arms and for modeling the impact
of the implementation strategies in larger
populations. We tested the DNA for 14 HPV types
(16, 18, 32, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68)
using CareHPV™ testing system. Collected
specimens were transported daily from the CHCs
and weekly from the health facilities to the study lab
at Migori County Hospital. Tests were run in
batches of 90, with a turnover time of approximately
1–2 weeks for results.
 Notification of HPV results: HPV test results were
preferentially sent to women via text message with
instructions about appropriate follow-up as
recommended by the Kenya Ministry of Health
guidelines. Messages were developed by key
stakeholders and women from the target population
during the focus group discussions. Women who did
not have access to a phone, or did not wish to
receive their results by SMS could opt for a return
visit to the clinic, or a home visit.
 Standard referral for treatment (both arms,
Phase 1): Women who were HPV-positive were
Fig. 2 Map of communities randomized to control and intervention activities in Migori, County Kenya. This map was developed by Easter Olwanda,
who has provided written permission for use in this publication
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referred to Migori County Hospital for a visual exam
with acetic acid and treatment with cryotherapy per
the WHO guidelines [44].
 In-depth participant interviews and focus
groups: We conducted semi-structured interviews
with randomly selected participants in both arms at
three key points in the cervical cancer prevention
cascade: screening delivery (n = 30), notification of
results (n = 30) and treatment access (all). Participants
were contacted either in person or by phone, and
interviews conducted in person by experienced
qualitative interviewers in the local language using
interview guides developed by the research team.
Topics explored in these interviews will elucidate ways
to make cervical cancer screening more acceptable and
accessible to women. Interviews captured quantitative
data about women’s participation in various aspects of
the prevention cascade. Interviewers then explored
women’s perspectives of their experience with the
intervention and explanatory factors related to the
decisions to access screening and treatment through
open-ended questions. Among women who did not
access treatment, we probed for factors or strategies
that would allow them to link to care in the future.
 Provider and key stakeholder interviews and
focus groups: During the cluster- randomized trial,
providers in the community health campaigns
underwent brief interviews at two time points: after
three and six campaigns had been completed. In the
clinic-arm, providers underwent interviews at three,
6 and 12 months into the intervention. These
interviews will help to understand explanatory
factors for the success or failure of the intervention
from a health system perspective. Interview topics
included personal attitudes and beliefs around
screening importance and feasibility, perceived and
actual barriers to implementation and potential
strategies to overcome provider, health delivery and
patient-level barriers to screening and treatment.
Intervention development and cluster randomized trial:
Phase 2
 Enhanced linkage to treatment: We will work
with health care providers, community members
and other stakeholders to review outcomes from the
quantitative, qualitative and process measures in
Phase 1, critically examine and modify the cervical
cancer screening strategy to develop and pilot the
enhanced linkage to treatment intervention over a
6–9 month period between Phase 1 and 2. We will
do this through a series of key stakeholder meetings,
followed by the establishment of smaller working
groups for the creation of the specific intervention
components. In the first set of meetings, we will
present the findings from Phase 1 and seek feedback
on representativeness and discuss implications for
culturally relevant intervention strategies. Options
for the most feasible and acceptable strategies to
increase the number of women linking to treatment
will be explored in the light of that data.
Criteria for potential strategies include: community-
developed, low-cost, feasible in all study communities,
and able to ensure treatment for HPV-positive women
in a timely manner in accordance with Ministry of
Health guidelines. In a second, small stakeholder meet-
ing, we will review potential strategies discussed and
developed in the first meeting, and discuss solutions
proposed in other settings, including the use of mobile
treatment units, transportation vouchers, and treatment
“navigators” to help women understand and travel to
treatment sites. Once the linkage intervention has been
defined, we will hold another working group with stake-
holders to create a standardized protocol, training man-
ual, standard operating procedures and data collection
instruments. After equipment procurement, provider
training and further outreach messaging, the enhanced
linkage strategy will be piloted in two to three Phase 1
intervention communities prior to launch of Phase 2.
Implementation framework
The study design, and outcome measures are centered
in the essential implementation metrics as defined by
the RE-AIM framework, which modified to the context
of our study (Table 1) [17]. Outcomes will be evaluated
through quantitative, qualitative and process measures.
This design will allow us to test the following
hypotheses:
 Community-based cervical cancer screening will
reach a larger portion of eligible women and be
more acceptable to patients and providers than
clinic-based testing. (REACH)
 A community-driven intervention will improve
linkage to treatment among women who need
treatment after an HPV-positive screening test
compared to standard referral. (EFFICACY)
 We will identify modifiable patient and health
system challenges that can be addressed to make
health campaign based HPV testing and enhanced
linkage to treatment succeed and be sustainable.
(ADOPTION & MAINTENANCE)
 Community-based cervical cancer screening with
enhanced linkage to treatment will have a greater
population-level health impact as measured in
women reached with screening and any necessary
treatment, and favorable cost-effectiveness profile
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compared to clinic-based strategies and standard
referral for treatment. (IMPLEMENTATION)
Participants
Our target population is women living in rural Kenya
who are eligible for and would benefit from cervical can-
cer screening per the Kenya Ministry of Health Guide-
lines (25–65 years old with an intact uterus and cervix).
The study population is women 25–65 years in the
twelve communities in the Nyanza Province who access
screening during both phases of the trial.
Recruitment and consent
Communities participating in the trial provided verbal
assent in the planning process with written consent ob-
tained from individuals for screening. Participants were
recruited through the community health campaigns and
in the clinics. Women within the target age range were
invited to attend the cervical cancer educational module.
After the health talk, women were asked to provide in-
formed consent by research assistants for a post-module
questionnaire and follow-up after screening completion.
Women who were not willing to provide informed con-
sent were still able to attend the health talk and have ac-
cess to the HPV screening strategy assigned to her arm,
but were not contacted for the follow-up in-depth inter-
views or participation in focus group discussions.
Primary and secondary endpoints
To determine the reach of cervical cancer screening
using HPV-testing in community health campaigns
compared to clinics, we are using the following metrics:
i) the absolute number of women who completed
screening in each arm and ii) the proportion of women
in each arm who completed screening. The total number
of women in each arm is the number of women 25–65
in each community as determined by census data.
Secondary outcomes will include iii) the proportion of
women who accept screening among women offered at
each site and iv) the proportion of women in the clinic-
based arm who request clinician-collected specimens.
To determine the efficacy of a community-developed
strategy to increase treatment access, we will compare
the efficacy of the community-based HPV testing with
standard versus enhanced linkage to treatment using the
following metrics: i) the number of women who receive
treatment after screening HPV + in the intervention
(Phase 1) compared to the enhanced intervention (Phase
2) and ii) the proportion of HPV-positive women in each
arm who complete treatment. Secondary outcomes that
address quality of care concerns for the models will
include iii) the proportion of women who receive the
correct treatment (per Ministry of Health protocol)
during a single treatment visit and iv) the average time
between HPV testing and access of treatment by arm.
Data collection
We collected data on both screening and linkage to
treatment from both control and intervention communi-
ties in Phase 1. Data was collected by members of the
research team and entered into pre-programmed tablet
computers using OpenDataKit software (ODK™),(https://
Table 1 A modified RE-AIM framework to evaluate community health campaign-based cervical cancer screening compared to
health-facility based screening
Dimension Goal Implementation Question Hypothesis
Reach Who is intended to benefit? How do we reach reproductive-aged
women in rural kenya?
A screening strategy offered through community
health campaigns in a central location will reach a
large proportion of reproductive-aged women.How do we reach them?
Effectiveness Is the program effective? Are women getting screened for
cervical cancer with HPV?
A community-based strategy allowing for
self-testing will be highly acceptable.
How do we ensure effectiveness? Are HPV + women successfully
linking to treatment?
Innovative, patient and provider-designed
strategies will increase the number of women
linking to care.
Adoption and
Maintenance
How can strategy be maintained
after initial implementation and
adopted in similar communities?
What are the patient, provider and
delivery system processes necessary to
ensure consistent service provision?
A screening protocol with a simple,
patient-performed test offered as part
of a health fair will minimize the costs to
the health care system to introduce screening.
What are the short and long-term
health effects in the community?
What is the population-level health impact
of screening using HPV self-testing in the
CHCs with enhanced linkage to care?
The high number of at -risk women reached
through the CHC-base strategy with enhanced
linkage to care would produce a greater
population-level health impact.
Implementation What is adherence to the
implementation strategy at
the delivery level?
Is HPV testing being offered and delivered
consistently at the CHC and clinic sites?
Providing testing in a high-volume CHC will reach
a large number of women with low staffing and
infrastructure needs, and will therefore have a
lower cost per woman treated than a
standard strategy.What are the costs of
implementation?
What is the cost per lesion treated?
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opendatakit.org) which had been used by this research
team for the past several years. Programming included
checks for range, structure, and internal consistency.
During the community-health campaigns, data was col-
lected directly from providers and participants into the
tablets and was transferred daily via a secure electronic
transfer to our data center facility in Kisumu, Kenya and
stored on a secure server. To capture visits and out-
comes from clinic-based screening and facility treat-
ment, a member of the research team visited each
clinical facility on a weekly basis to enter data from Min-
istry of Health registers and study-specific forms into
the tablets. Data transfer from clinical-sites took place
weekly. The same data collection procedures will be ap-
plied in Phase 2.
Implementation consistency
All four basic components of the intervention (outreach/
education, HPV-testing, notification of results and
linkage to treatment) were monitored throughout Phase
I of the trial to ensure maintained fidelity to the protocol
and quality of service and message delivery. Quantitative
outcome measures, as well as the process measures
listed below assessed continued fidelity of the interven-
tion as offered. Qualitative data from in-depth inter-
views, focus-group discussions and process measures
will provide a more complete picture about subtle but
important factors that may influence the actual service
delivery and uptake.
Sample size
Using estimates from the 2009 Kenya census [45] with
projected population growth for 2015 and results from
recent community-wide census enumeration carried out
by a cluster randomized trial in an adjacent district [46],
we have estimated the total available population of
women to be approximately 1000 per community of
5000. The estimates for attendance at community health
campaigns (60% or 600 women) and clinics (30% or 300
women) and screening uptake were based on our forma-
tive work, community health campaign attendance in
adjacent districts, and prior studies of self-collected
HPV testing [27, 28, 47]. Our assumptions were that (1)
attendance would be higher at community health cam-
paigns and (2) screening uptake would be higher among
women attending community health campaigns because
most women attend based on outreach messaging
around cervical cancer. These assumptions suggested a
study population of 510 women per community acces-
sing testing through community health campaigns and
210 accessing screening through clinics. For Phase 1, the
total number of women accessing screening in the six
communities randomized to community health
campaigns would be 3060 and 1260 in communities
randomized to clinic-based testing. We used these
conservative estimates for sample size calculations (see
below), but allocated resources for up to 4500 women in
the community-testing arm and 2000 women in the
clinic-based screening arm to ensure continuity of study
activities. We also enrolled all providers and targeted
key ministry of health stakeholders for quantitative and
qualitative assessments of barriers and facilitators to
care. A representative subset of this group were invited
to participate in meetings to develop the enhanced
linkage intervention.
Statistical analysis
 Preliminary Analysis: For each outcome, we will
produce descriptive statistics (frequencies,
proportions, etc.) overall, across clusters of interest
(community, clinic, provider, etc.), and over time.
We will also graph these data to identify visual
trends.
 Primary and Secondary Analysis: Although this is a
community-level intervention, the main outcomes
will be analyzed at the individual level. We will
compare the number and proportion of women who
screen for HPV (reach) and who get treated for a
positive HPV test (efficacy) in communities assigned
to community vs. clinic-based testing using
generalized estimating equations to account for the
correlation among observations within communities.
Efficacy: We will employ a log link and Poisson
distribution with an offset term to represent the size
of each community.
 Power calculations: We anticipate being able to
observe a 30% difference in overall screening uptake
between the control and intervention arms, a
conservative estimate relative to previous cluster
randomized trials. The power calculations assume an
alpha of 0.05, a beta of 0.20, and an intracluster
correlation coefficient of 0.072 for screening and
0.11 for treatment, based on calculations from a
cluster-randomized trial of HPV efficacy [5].
Cost-effectiveness analysis (maintenance)
We assessed the costs, population health impact, and
incremental cost effectiveness of three intervention strat-
egies (clinic-based screening with standard linkage to
treatment; community screening with standard linkage;
and will assess community screening with enhanced
linkage). To do this, we undertook a micro-costing of
the resources needed to carry out the activities in both
arms in Phase 1 and 2. Costing included 1) personnel
(including fringe benefits); 2) recurring supplies and
services; 3) capital and equipment; and 4) facility space.
Intervention costs were assessed using a uniform cost
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data collection protocol to quantify resources used and
associated costs in each of the study sites (community-
health campaigns, clinics, laboratories and district hospi-
tals). Data was obtained through administrative record
review and interviews with administrative, finance and
human resources staff, supplemented by direct observa-
tion in a limited number of staff “time and motion”
studies in order to distinguish cervical cancer-related
activities from other health services delivered by the
same personnel. Costs were summarized as total
program costs as well as costs per woman screened and
per HPV positive women treated.
We observed study outcomes to estimate the health
outcomes associated with each screening and linkage
strategy. Observed data include will include the number
of women screened and treated for high-risk HPV, the
proportion of women undergoing cryotherapy vs. LEEP,
and the side effects associated with each treatment. We
will find the best possible available data to estimate the
prevalence of various HPV-subtypes in the region, and
the associated risks of cervical intraepithelial neoplasia
(CIN), recurrence rates of CIN after treatment, and inva-
sive cancer in women with and without treatment. We
will translate each health event into a standard metric of
burden of disease, Disability-Adjusted Life Years
(DALYs), which combines morbidity (and associated
disability) with premature mortality (lost “life years”).
We will use the micro-costing described above to esti-
mate several indices comparing costs to desired program
outcomes: cost per case of HPV detected; cost per case
of CIN detected; cost per woman successfully linked to
facilities for treatment; and cost per woman treated. We
will construct a decision model to estimate the health
impact of HPV screening and linkage to treatment in a
population cohort of 1000 women. This model will
explicitly portray the paths from HPV to detection (by
clinical presentation or screening), the risks of clinical
progression, and outcomes with and without treatment
(early or late). It will incorporate data on local epidemi-
ology (HPV prevalence and cervical cancer, from Phase
1 and existing surveillance data); the clinical course of
HPV and cervical cancer (from scientific literature); and
the effectiveness of treatment (with cryotherapy and LEEP,
as well as for more advanced disease, from scientific
literature). Model outcomes will include deaths from
cervical cancer, lost years of life, and morbidity (short and
long-term), and DALYs (disability adjusted life years).
We will use the decision-analysis model to assess the
incremental cost-effectiveness ratio (ICER), defined as
the added cost per DALY averted, when comparing
intervention strategies. We will also calculate the ICER
compared to the current standard, which is no organized
available screening, using baseline data of screening
availability and use to calculate this. We will also
estimate the costs for scaled-up replication, which will
include variations in the number of and costs for
personnel, community-health campaign structure and
duration, HPV screening test costs laboratory costs and
different linkage strategies.
Process measures
We will use quantitative process analyses to evaluate the
strategy implemented in both arms at four levels of the
intervention delivery process (Fig. 3). These include a)
the proportion of women from each community health
campaign offered HPV testing or referral (community
health campaign-level processes); b) the proportion of
HPV tests for which valid results are available (specimen
transport and laboratory processes); c) the proportion of
women who receive their test results (community health
worker processes); and c) the proportion of HPV+
women attending a treatment visit who receive the
appropriate treatment per Kenya Ministry of Health
guidelines (health delivery center processes). We will use
data from the provider and participant interviews and
focus groups to explore the factors impacting the
relevant service delivery processes that affect the overall
result though quantitative and qualitative measures as
well as explore additional key barriers and facilitators to
both screening and treatment. Focus group data will
enrich these conclusions and be used to develop an
enhanced linkage intervention.
Ethical review
The trial was reviewed by an implementation and
dissemination science section at the National Cancer
Institute prior to funding. Ethical approval was obtained
by the Committee for Human Research at the University
of California, San Francisco (#14–13,698), Duke University
Institutional Review Board (Pro0007742), and the Scientific
and Ethical Review Unit at the Kenya Medical Research
Institute (SERU 2918). Any major protocol changes will be
communicated to all three review boards and to the trial
registry at ClinicalTrials.gov. Complete trial registry data is
available in a Additional file 1.
Trial status
Focus Group Discussions and in-depth interviews with
key informants took place in August and September
2015. A pilot campaign took place in December 2015.
Screening activities and enrollment in Phase I of the
cluster-randomized trial were carried out between
January and September 2016. We are now sharing feedback
of Phase I results and observations with various stake-
holders (community members, health care providers, and
health management teams) in preparation for FGDs and
working groups, which are aimed at enabling us design a
strategy for enhanced linkage to treatment.
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Discussion
Substantial progress toward cervical cancer prevention
has been made through research validating low-cost
screening strategies that have been included in national
and international protocols and guidelines. However, like
many international guidelines, the WHO cervical cancer
guidelines lacks advice on active implementation strat-
egies [48]. While this is partly due to an emphasis on
the clinical portion of the guidelines, some of this can be
attributed to the lack of effective implementation strat-
egies. Our goal with this novel study is to work with the
community using a rigorous implementation framework
to develop a strategy that could be scaled to improve
the reach and efficacy of cervical cancer prevention
programs in rural Africa, where the lack of health
care infrastructure and services has lead to poor
health outcomes. We are also hoping that the meth-
odology of this project can be expanded to develop
implementation strategies that would help address
other health care needs.
Based on our formative work, we expect that
community-based cervical cancer screening will reach a
substantially larger portion of eligible women than
clinic-based testing. Our findings will help guide imple-
mentation and optimization of a community-based HPV
testing model. While we anticipate that the community-
driven enhanced intervention will be more effective at link-
ing women to facilities for treatment than the standard re-
ferral system, this study will allow us to test both models
and look at various aspects of implementation, including
cost-effectiveness. In addition to these findings, we will
provide a model for a successful strategy to link women to
treatment within cervical cancer screening program and to
provide program leaders and policymakers with a tool kit
to design and evaluate a context-specific enhanced linkage
strategy that could be implemented in their own settings.
We expect that community-based HPV screening will have
a greater cost effectiveness and public health impact than
clinic-based testing, and that enhanced linkage strategies
will amplify these differences. Overall, our findings will
provide evidence to inform clinical protocols and govern-
ment policy regarding the provision of cervical cancer pre-
vention strategies and provide a guide for adaptation and
evaluation of similar programs in other settings. Ultimately
programs that both use evidence-based techniques and
reach a large proportion of the population will impact the
millions of women at risk for cervical cancer in low re-
source countries worldwide.
Conclusions
This project will have broad implications at both local
and national policy and planning levels, given the
enthusiasm of the Kenya Ministry of Health and
Division of Reproductive Health to implement na-
tional cervical cancer prevention strategies and their
partnership in this project. When the analyses are
complete, we will have produced a comprehensive de-
scription of barriers and facilitators to providing clinic
and community-based cervical cancer screening through
HPV testing, determined which strategy has greater reach
and a better cost-effectiveness profile, and developed a
strategy to improve linkage to treatment in partnership
with the community. If a community-based screening
strategy is shown to have more reach with a favorable
cost-effectiveness profile, this could be a viable strategy for
roll-out in similar settings in Kenya and possibly for adap-
tation to other East African countries with a high cervical
cancer burdens. Just as importantly, if community-based
testing is more effective and scalable than clinic-based
testing, we will explore factors necessary to improve
access to clinic for cervical cancer screening and other
preventive care services.
Fig. 3 Quantitative process measures for four aspects of cervical cancer prevention program delivery
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